Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (Atripla)

The Latest

Racial Differences Seen in Comparison of Stribild and Atripla as First-Line Therapy Img
Conference Coverage

Racial Differences Seen in Comparison of Stribild and Atripla as First-Line Therapy

A new study finds that black people are less likely to keep their viral load down on Atripla -- and that more trouble with side effects may be the reason.

Promo Image

Sustiva, Atripla Tied to Neurologic Toxicity

A team of researchers from Johns Hopkins University School of Medicine reported that the way the body metabolizes the HIV medication efavirenz may contribute to cognitive (brain function-related) impairment. Efavirenz is sold under the brand name Sus...

Antiretroviral Rounds: Resistance on Two Fronts Img

Antiretroviral Rounds: Resistance on Two Fronts

Got this challenging curbside consult from a colleague, and it has a interesting wrinkle:

I have a longstanding patient with HIV who had many failed regimens in the 1990's with resultant following mutations on a genotype done in 2003:

NRTI (M1...

Promo Image

20% People Switch Atripla Due to Efavirenz Side Effects: Late Switches Are Common

The experience from use of fixed-dose combination, efavirenz-based treatment (Atripla) as first-line therapy in the UK was published ahead of print in the journal AIDS.

This analysis included 472 patients from the Chelsea and Westminster Hospital in...

Promo Image


Brand name: Atripla

Generic name: efavirenz/emtricitabine/tenofovir, or EFV/FTC/TDF

Class: NNRTI and NRTI -- single-tablet regimen (STR)

Manufacturer: Bristol-Myers Squibb,, (800) 321-1335, and Gilead Sciences,, (800) GI...

Promo Image
Conference Coverage

Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study

Seattle, Wash. -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced full Phase 3 clinical trial results from pivotal Study 102 demonstrating that the Quad, a once-daily single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir...

Promo Image

Complera and Atripla News

Last summer, 48-week data won FDA approval for Complera (see the November/December 2011 "Briefly" for the complicated details). At IDSA, 96-week data were presented from the ECHO and THRIVE studies that pitted the new Complera against Atripla. Comple...

Promo Image

Switching From Atripla to Complera

Now that the best-selling Atripla has a real competitor, an important question becomes, can people switch from Atripla to the new Complera?

While switching to a new and improved drug or regimen is common, there was a concern about switching here bec...

ICAAC HIV Poster Roundup #1: Clinically Relevant Findings Img

ICAAC HIV Poster Roundup #1: Clinically Relevant Findings

Here's a quick sampling of some of the more noteworthy HIV-related posters presented at a major research conference last week. Topics covered include a surprisingly high frequency of people quitting Atripla due to side effects; the decline of multidr...

Promo Image

Atripla's Co-Pay Program Now Saves More Money

The co-pay program for Atripla now eliminates the requirement that people first pay $50 out-of-pocket before financial assistance begins. The same is true for the drugs that make up Atripla (Sustiva and Truvada), as well as the medications that make ...